Nguyen
01-30-2020, 05:19 PM
Given that Neratinib has been out not that long ago, and already resistance to it has developed as in
Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.
https://www.ncbi.nlm.nih.gov/pubmed/28152547
The below news is welcome. Essentially Neratinib and Affinitor could overcome this resistance.
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers
https://www.sciencedirect.com/science/article/abs/pii/S1535610819305835?via%3Dihub
Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4.
https://www.ncbi.nlm.nih.gov/pubmed/28152547
The below news is welcome. Essentially Neratinib and Affinitor could overcome this resistance.
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers
https://www.sciencedirect.com/science/article/abs/pii/S1535610819305835?via%3Dihub